Takeda returns ferumoxytol rights to AMAG

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) regained territorial rights to Feraheme ferumoxytol from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) after the companies terminated a 2010 deal. AMAG now has worldwide rights to the drug.

Takeda had marketed the IV iron replacement therapy as Feraheme in Canada and as Rienso in the EU to treat iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). It paid AMAG $60 million up front in the 2010 deal, which gave it exclusive rights to Feraheme in those territories as well as Turkey, Switzerland and certain Asia-Pacific territories, excluding Japan, China and Taiwan. ...